X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (293) 293
rheumatology (213) 213
female (185) 185
index medicus (177) 177
middle aged (177) 177
male (173) 173
adult (142) 142
rheumatoid arthritis (109) 109
aged (104) 104
life sciences (65) 65
treatment outcome (63) 63
arthritis, rheumatoid - drug therapy (57) 57
antirheumatic agents - therapeutic use (56) 56
arthritis (52) 52
immunology (52) 52
abridged index medicus (45) 45
severity of illness index (41) 41
internal medicine (39) 39
rituximab (39) 39
retrospective studies (38) 38
disease (36) 36
risk factors (35) 35
human health and pathology (34) 34
systemic sclerosis (33) 33
antirheumatic agents - adverse effects (32) 32
double-blind (32) 32
rheumatoid-arthritis (32) 32
autoantibodies (31) 31
prospective studies (31) 31
scleroderma (31) 31
infliximab (30) 30
france (28) 28
medicine, general & internal (28) 28
care and treatment (27) 27
efficacy (27) 27
arthritis, rheumatoid - immunology (26) 26
lupus (26) 26
research (26) 26
rhumatology and musculoskeletal system (26) 26
adolescent (25) 25
autoimmunity (25) 25
classification (25) 25
rheumatoid factor (25) 25
antibodies, monoclonal - therapeutic use (23) 23
autoimmune diseases (23) 23
methotrexate (23) 23
mortality (23) 23
tumor necrosis factor-alpha - antagonists & inhibitors (23) 23
inflammation (22) 22
therapy (22) 22
analysis (21) 21
case-control studies (21) 21
criteria (21) 21
etanercept (21) 21
expression (21) 21
polyarthrite rhumatoïde (21) 21
research article (21) 21
systemic lupus erythematosus (21) 21
young adult (21) 21
[ sdv.mhep.rsoa ] life sciences [q-bio]/human health and pathology/rhumatology and musculoskeletal system (20) 20
antibodies (20) 20
diagnosis (20) 20
prevalence (20) 20
clinical trials (19) 19
follow-up studies (19) 19
safety (19) 19
treatment (19) 19
dermatomyositis (18) 18
drug therapy (18) 18
patients (18) 18
polymyositis (18) 18
studies (18) 18
survival (18) 18
aged, 80 and over (17) 17
biomarkers (17) 17
cohort studies (17) 17
disease-activity (17) 17
time factors (17) 17
animals (16) 16
france - epidemiology (16) 16
health aspects (16) 16
myositis (16) 16
1506 (15) 15
[sdv.mhep.rsoa]life sciences [q-bio]/human health and pathology/rhumatology and musculoskeletal system (15) 15
arthritis, rheumatoid - pathology (15) 15
association (15) 15
genetic predisposition to disease (15) 15
genotype (15) 15
risk (15) 15
scleroderma, systemic - genetics (15) 15
sjogren's syndrome (15) 15
arthritis, rheumatoid - complications (14) 14
arthritis, rheumatoid - genetics (14) 14
arthritis, rheumatoid - physiopathology (14) 14
cells, cultured (14) 14
disease progression (14) 14
immunotherapy (14) 14
multivariate analysis (14) 14
scleroderma, systemic - complications (14) 14
systemic scleroderma (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 09/2016, Volume 316, Issue 11, pp. 1172 - 1180
IMPORTANCE: One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing... 
AGENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER | ADALIMUMAB | ANTITUMOR-NECROSIS-FACTOR | INADEQUATE RESPONSE | RITUXIMAB | DOUBLE-BLIND | OUTCOMES | INHIBITOR | ABATACEPT | Care and treatment | Research | Tumor necrosis factor | Rheumatoid arthritis | Clinical trials | Tumor necrosis factor-TNF | TNF inhibitors
Journal Article
Journal of Internal Medicine, ISSN 0954-6820, 04/2014, Volume 275, Issue 4, pp. 398 - 408
Objectives The aim of this study was to investigate whether the quadrivalent human papillomavirus (HPV) vaccine Gardasil is associated with a change in the... 
vaccine safety | autoimmune disorders | human papillomavirus vaccine | systematic case–control study | human papillomavirus | vaccination | Vaccine safety | Human papillomavirus | Systematic case-control study | Human papillomavirus vaccine | Autoimmune disorders | Vaccination | SYSTEMIC-LUPUS-ERYTHEMATOSUS | IMMUNE THROMBOCYTOPENIC PURPURA | systematic case-control study | GUILLAIN-BARRE-SYNDROME | CHILDREN | IMMUNIZATION | MEDICINE, GENERAL & INTERNAL | MULTIPLE-SCLEROSIS | DATABASE | SURVEILLANCE | INFLUENZA VACCINATION | DIAGNOSTIC-CRITERIA | Autoimmune Diseases - epidemiology | France - epidemiology | Humans | Mass Vaccination - statistics & numerical data | Risk Factors | Autoimmune Diseases - immunology | Autoimmune Diseases - etiology | Case-Control Studies | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | Incidence | Alphapapillomavirus | Young Adult | Connective Tissue Diseases - immunology | Papillomavirus Infections - prevention & control | Purpura, Thrombocytopenic, Idiopathic - immunology | Adolescent | Multiple Sclerosis - immunology | Papillomavirus Infections - immunology | Papillomavirus Vaccines - adverse effects | Adult | Female | Diabetes Mellitus, Type 1 - immunology | Papillomavirus Vaccines - administration & dosage | Papillomaviruses | AIDS vaccines | Guillain-Barre syndrome | Type 1 diabetes | Analysis | Oral contraceptives | Life Sciences
Journal Article
Journal Article
Arthritis Care & Research, ISSN 2151-464X, 04/2017, Volume 69, Issue 4, pp. 528 - 535
Journal Article
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 08/2018, Volume 77, Issue 8, pp. 1143 - 1150
ObjectiveTo compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission... 
granulomatosis with polyangiitis | ANCA vasculitis | ANCA | CD19+ B lymphocytes | microscopic polyangiitis | WEGENERS-GRANULOMATOSIS | B-CELLS | MAINTENANCE | RELAPSES | REFRACTORY GRANULOMATOSIS | SYSTEMIC VASCULITIS | DISEASE | ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES | RENAL INVOLVEMENT | INDUCTION | RHEUMATOLOGY | Recurrence | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Drug Monitoring - methods | Rituximab - therapeutic use | Antirheumatic Agents - adverse effects | Adult | Female | Remission Induction - methods | Antirheumatic Agents - therapeutic use | Rituximab - adverse effects | Severity of Illness Index | B-Lymphocyte Subsets - drug effects | Drug Administration Schedule | Kaplan-Meier Estimate | Biomarkers - blood | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Rituximab - administration & dosage | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology | Lymphocyte Count | Aged | Infusions, Intravenous | Precision Medicine - methods | Antibodies, Antineutrophil Cytoplasmic - blood | CD19 antigen | Rheumatology | Granulomatosis | Rituximab | Arthritis | Patients | Studies | Cyclophosphamide | Vasculitis | Dyspnea | Lymphocytes B | Medical prognosis | Antineutrophil cytoplasmic antibodies | Remission | Methotrexate | Cytoplasm | Life Sciences | Human health and pathology | Rhumatology and musculoskeletal system
Journal Article
Journal Article